AQR Capital Management
NBSE

AQR Capital Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

AQR Capital Management’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-33
Closed -$33K – 2281
2015
Q2 		$33K Hold
33
– – ﹤0.01% 2201
2015
Q1 		$33K Hold
33
– – ﹤0.01% 2126
2014
Q4 		$109K Hold
33
– – ﹤0.01% 2432
2014
Q3 		$95K Hold
33
– – ﹤0.01% 2449
2014
Q2 		$125K Hold
33
– – ﹤0.01% 2443
2014
Q1 		$178K Buy
+33
New +$174K ﹤0.01% 2451

Other funds holding NBSE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SIP
Stoneridge Investment Partners Radnor, Pennsylvania $138M AUM 7.66% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
GBA
Garrison Bradford & Associates New York $88.4M AUM 15.86% 1-Year Est. Return
HF
Hoxton Financial Shepherdstown, West Virginia $194M AUM 6.21% 1-Year Est. Return

AQR Capital Management's NBSE Position: Q3 2015 in Review

AQR Capital Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q3 2015, closing a stake of 33 shares — an estimated $33K sold.

AQR Capital Management first reported a position in NBSE in Q1 2014 and held it in 6 quarters. The position peaked at $178K in Q1 2014. 47 funds tracked by Wall St. Rank hold NBSE as of Q3 2015.

  • AQR Capital Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
  • AQR Capital Management sold 33 NeuBase Therapeutics, Inc. Common Stock shares in Q3 2015, an estimated $33K.
  • AQR Capital Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q1 2014 and held it in 6 quarters.
  • AQR Capital Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $178K in Q1 2014.
  • 47 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q3 2015.

Based on AQR Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.